Telomir Pharmaceuticals Inc. Common Stock (TELO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Telomir Pharmaceuticals I...

    NASDAQ: TELO · Real-Time Price · USD
    1.34
    -0.05 (-3.60%)
    At close: Sep 29, 2025, 3:59 PM

    Telomir Pharmaceuticals Common Stock Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a n/a
    Operating Income
    		 -12.24M -3.94M -854.15K -138.13K
    Interest Income
    		 48K n/a n/a n/a
    Pretax Income
    		 -16.53M -13.07M -854.15K -138.13K
    Net Income
    		 -16.53M -13.07M -854.15K -138.13K
    Selling & General & Admin
    		 9.64M 600.19K 20.94K 11.64K
    Research & Development
    		 2.24M 1.57M 833.21K 126.49K
    Other Expenses
    		 370.5K n/a n/a n/a
    Operating Expenses
    		 12.24M 3.94M 854.15K 138.13K
    Interest Expense
    		 -4.34M 1.64M n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 12.24M 3.94M 854.15K 138.13K
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 29.54M 29.61M 29.61M 29.61M
    Shares Outstanding (Diluted)
    		 29.54M 29.61M 29.61M 29.61M
    EPS (Basic)
    		 -0.56 -0.44 -0.03 -0.00
    EPS (Diluted)
    		 -0.56 -0.44 -0.03 -0.00
    EBITDA
    		 -12.19M -11.43M -854.15K -138.13K
    EBIT
    		 -12.19M -11.43M -854.15K -138.13K
    Depreciation & Amortization
    		 12.24M -7.49M 854.15K 138.13K

    Add to Watchlist